Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study

Hematological Oncology, Journal Year: 2025, Volume and Issue: 43(2)

Published: Feb. 3, 2025

ABSTRACT This multicenter real‐world analysis evaluated the efficacy of isatuximab, pomalidomide, and dexamethasone (IsaPd) in 51 patients with multiple myeloma (MM) who were refractory to daratumumab (Dara‐R). The majority under 70 years old (60.8%), predominantly female (56.9%), heavily pretreated, 74.5% being triple‐class (TCR); 32.1% 28 cytogenetic data had high‐risk abnormalities. overall response rate (ORR) was 56.9%, including 3 stringent complete (sCR), 4 CR, 7 very good partial (VGPR). Neither age, number prior therapies, TCR status, nor time from Dara refractoriness IsaPd initiation significantly affected rates. Median progression‐free survival (PFS) 5.8 months, a 12‐month PFS probability 30.6%. Baseline hemoglobin (Hb) levels key predictor PFS: Hb < 11.8 g/L 3.5‐fold increased risk progression, median 4.6 months compared 22 those higher Hb. (OS) 21.0 OS 63.4%. Lower (< 11 g/L) associated tenfold mortality. Among underwent FISH analysis, while no significant difference mortality observed, abnormalities exhibited nearly disease progression. These results suggest that offers meaningful option for Dara‐R patients, serving as critical both OS. However, remains modest, underscoring need novel combination therapies.

Language: Английский

Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1168 - 1168

Published: March 30, 2025

The therapeutic landscape for multiple myeloma has gradually expanded in recent decades, leading to unprecedented deep and sustained responses as well remarkable improvements patient survival. Nonetheless, changes treatment algorithms have raised new demands patients with relapsed/refractory disease, prior exposure refractoriness therapies impact the choice of subsequent treatments. In particular, lenalidomide-an established backbone both front-line maintenance settings a key component many approved regimens used relapsed disease-is associated suboptimal clinical outcomes. Therefore, identifying most appropriate management lenalidomide-refractory patients, even more so who are refractory than one agent, is critical. At present, options this growing subgroup still limited; however, data from research promising. Herein, we summarized currently available discuss future directions based on latest results ongoing trials.

Language: Английский